- Home
- HRMY vs PGNY Comparison
HRMY vs PGNY Comparison
Compare HRMY & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | PGNY |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HRMY | PGNY |
|---|---|---|
| Price | $37.82 | $25.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $51.33 | $27.44 |
| AVG Volume (30 Days) | 695.1K | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | 2.96 |
| EPS | ★ 3.17 | 0.62 |
| Revenue | $825,944,000.00 | ★ $1,268,689,000.00 |
| Revenue This Year | $23.11 | $11.55 |
| Revenue Next Year | $16.15 | $9.52 |
| P/E Ratio | ★ $12.04 | $41.80 |
| Revenue Growth | ★ 21.13 | 11.41 |
| 52 Week Low | $25.52 | $14.32 |
| 52 Week High | $40.93 | $27.76 |
Technical Indicators
Market Signals| Indicator | HRMY | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 52.53 |
| Support Level | $37.12 | $25.14 |
| Resistance Level | $39.60 | $27.76 |
| Average True Range (ATR) | 1.15 | 0.91 |
| MACD | -0.38 | -0.18 |
| Stochastic Oscillator | 17.33 | 33.24 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.